Aurobindo Pharma

AUROPHARMA

INE406A01037

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 07:40:29 2024-04-24 am EDT			5-day change	1st Jan Change
1,084 ^INR	-0.84%		-2.43%	+0.00%

Apr. 07	Aurobindo Pharma Limited Announces Appointment of T. Vijaya Kumar as President R&D (Specialty Drug Delivery)	CI
Apr. 02	Aurobindo Pharma Arms Commission Four New Plants in Andhra Pradesh, India	MT

Aurobindo Pharma : Receives FDA Approval for Diclofenac Potassium Capsules, 25mg

October 21, 2021 at 07:15 am EDT

East Windsor, N.J. - Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Diclofenac Potassium Capsules, 25mg. Aurobindo Pharma's Diclofenac Potassium Capsules, 25mg are an AB-rated generic equivalent to the reference listed drug (RLD), Zipsor Capsule of Assertio Therapeutics, Inc.

Contact:

279 Princeton Hightstown Road

East Windsor

NJ 08520

T: 866-850-2876

Latest news about Aurobindo Pharma

Aurobindo Pharma Limited Announces Appointment of T. Vijaya Kumar as President R&D (Specialty Drug Delivery)	Apr. 06	CI
Aurobindo Pharma Arms Commission Four New Plants in Andhra Pradesh, India	Apr. 02	MT
Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024	Mar. 27	CI
Indian shares set to track Asian peers higher, eye on Fed meet	Mar. 19	RE
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	Mar. 19	MT
Aurobindo Pharma Limited Receives Final Approval from the US Food & Drug Administration	Mar. 19	CI
Aurobindo Pharma Arm Restarts Distribution of Aseptic Products from Unit III	Mar. 12	MT
APL Healthcare Limited Subsidiary of Aurobindo Pharma Limited Announces Unit Inspection Team of World Health Organization Conducts an Inspection at the Unit IV	Mar. 11	CI
Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer	Mar. 05	CI
Aurobindo Pharma Limited Receives USFDA Approval for Fingolimod Capsules, 0.5 Mg	Mar. 01	CI
Indian shares set to rise on strong domestic growth, in-line US inflation data	Feb. 29	RE
US FDA Completes Inspection of Aurobindo Pharma's Injectibles Unit	Feb. 29	MT
US FDA Clears Aurobindo Pharma Arm's Manufacturing Unit in Telangana, India	Feb. 16	MT
INDIA STOCKS-Auto stocks drive Indian shares higher	Feb. 16	RE
Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg	Feb. 12	CI
INDIA STOCKS-Energy shares drag India's blue-chip stocks; small, mid-caps slide	Feb. 12	RE
Transcript : Aurobindo Pharma Limited, Q3 2024 Earnings Call, Feb 12, 2024	Feb. 11
Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director	Feb. 10	CI
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO	Jan. 23	RE
Aurobindo Pharma's Telangana Facility Receives 'Voluntary Action Indicated' Classification from US FDA	Jan. 09	MT
Aurobindo Pharma Unit Gets US FDA's Final Approval for Generic Anfi-Fungal Drug	Dec. 27	MT
Aurobindo Gets 10 Observations from US FDA for Subsidiary's New Jersey Injectable Plant	Dec. 26	MT
Aurobindo Pharma Arm Gets US FDA's Final Approval for Generic Asthma Maintenance Treatment	Nov. 30	MT
Aurobindo Pharma Gets Final US FDA Nod for Darunavir Tablets	Nov. 29	MT
Aurobindo Pharma Receives USFDA Approval for Darunavir Tablets, 600 mg and 800 mg	Nov. 29	CI

Chart Aurobindo Pharma

Duration

Period

More charts

Company Profile

Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families : - generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases; - active pharmaceutical ingredients. At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil. Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Aurobindo Pharma

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,084 INR

Average target price

1,190 INR

Spread / Average Target

+9.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AUROBINDO PHARMA	+0.00%	7.69B
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals